Selective Estrogen Receptor Modulators

Southern Medical Journal

Volumn 96, Issue 5, 2003, Pages 469-476

  Haskell, Sally G ^a  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1,2 TRIPHENYLETHYLENE DERIVATIVE; ARZOXIFENE; BENZOTHIOPHENE DERIVATIVE; CLOMIFENE CITRATE; CONJUGATED ESTROGEN; DROLOXIFENE; IDOXIFENE; MEDROXYPROGESTERONE ACETATE; MIPROXIFENE PHOSPHATE; OSPEMIFENE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAMOXIFEN DERIVATIVE; TOREMIFENE; UNCLASSIFIED DRUG; ESTROGEN RECEPTOR;

ADULT; ADVANCED CANCER; ANIMAL MODEL; BONE; BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; ENDOMETRIAL DISEASE; ENDOMETRIUM; FEMALE; FEMALE INFERTILITY; HEART INFARCTION; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; NONHUMAN; OSTEOPOROSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; RAT; REVIEW; SIDE EFFECT; STROKE; VAGINA DISCHARGE; BREAST; BREAST TUMOR; INFERTILITY; MALE;

BONE AND BONES; BREAST; BREAST NEOPLASMS; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; ENDOMETRIUM; FEMALE; HUMANS; INFERTILITY; MALE; OSTEOPOROSIS; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0042467585     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.SMJ.0000051146.93190.4A     Document Type: Review

References (84)

1. Campbell S, Whitehead M. Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynecol 1977;4:33-47.
2. The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: Results from the Post-Menopausal Estrogen/Progestin Intervention Trial. JAMA 1996;276:1389-1396.
3. The Writing Group for the PEPI Trial. The effects of estrogen or estrogen/progesterone regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199-208.
4. Grodstein F, Stampfer MS, Colditz GA, Willett WL, Mansan JE, Joffee M, et al. Postmenopausal estrogen therapy and mortality. N Engl J Med 1997;336:1769-1775.
5. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-491.
6. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-613.
7. Jordan VC. Designer estrogens. Sci Am 1998;279:60-67.
8. Greene GL, Gilna P, Waterfield M, Barber A, Hort Y, Shine J. Sequence and expression of human estrogen receptor complementary DNA. Science 1986;231:1150-1154.
9. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93:5925-5930.
10. Peterson CM. Estrogen and progesterone receptors: An overview for the year 2000. J Soc Gynecol Investig 2000;7(1 Suppl):S3-S7.
11. Hurd C, Moudgil VK. Steroid hormone receptor families, in Conn PM, Goodman HM (eds): Handbook of Physiology: Section 7 - The Endocrine System: Volume 1 - Cellular Endocrinology. New York, Oxford University Press, 1998, pp 383-411.
12. Shibata H, Spencer TE, Ohate SA, Jenster G, Tsai SY, Omalley BW. Role of coactivators and corepressors in the mechanism of steroid/thyroid receptor action. Recent Prog Horm Res 1997;52:141-165.
13. Giguere V, Tremblay A, Tremblay GB. Estrogen receptor B: Reevaluation of estrogen and anti-estrogen signaling. Steroids 1998;63:335-339.
14. Adashi EY. Ovulation induction: clomiphene citrate, in Adashi EY, Rock JA, Rosenwaks Z (eds): Reproductive Endocrinology, Surgery, and Technology. Philadelphia, Lippincott-Raven, 1996, pp 1181-1206.
15. Stewart PJ, Stern PH. Effects of antiestrogens tamoxifen and clomiphene on bone resorption in vitro. Endocrinology 1986;8:125-131.
16. Plouffe L. Selective estrogen receptor modulators in clinical practice. J Soc Gynecol Investig 2000;7(1 Suppl):S38-S46.
17. Jones GS, Demoraes-Ruehsen N. Induction of ovulation with human gonadotropins with clomiphene. Fertil Steril 1965;16:461.
18. Zeneca Pharmaceuticals. Nolvadex (package insert). Wilmington, DE, Zeneca Pharmaceuticals, 1998.
19. Barr Laboratories. Tamoxifen citrate (package insert). Pomona, NY, Barr Laboratories.
20. Jordan VC. Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res Treat 1994;31:41-52.
21. Murphy LC. Antiestrogen action and growth factor regulation. Breast Cancer Res Treat 1994;31:61-71.
22. Haran FE, Maretzek AF, Goldberg I, Horowitz A, Degani H. Tamoxifen enhances cell death in implanted MLF7 breast cancer by inhibiting endothelium growth. Cancer Res 1994;54:5511-5514.
23. The Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998; 351:1451-1467.
24. Saez RA, Osborne CK. Hormonal treatment of advanced breast cancer, in Kennedy BJ (ed): Current Clinical Oncology: Breast Cancer. New York, Alan R. Liss, 1989, vol 1, pp 163-172.
25. Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, et al. Prognostic significance of progesterone receptor levels in estrogen receptor positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective South West Oncology Group study. J Clin Oncol 1992;10:1284-1291.
26. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
27. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, et al. Interim analysis of incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 1998;352: 98-101.
28. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, et al. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomized trial among hysterectomized women. Lancet 1998;352:93-97.
29. Mitlak BH, Cohen FJ. Selective estrogen receptor modulators: A look ahead. Drugs 1999;57:653-663.
30. Goldstein SR. Effect of SERMs on breast tissue. J Endocrinol Invest 1999;22:636-640.
31. Turken S, Siris E, Seldin D, Flaster E, Hyman G, Lindsay R. Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst 1989;81:1086-1088.
32. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-856.
33. Delmas PD, Balena R, Contavreux E, Hardouin C, Hardy P, Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind placebo controlled study. J Clin Oncol 1997;15:955-962.
34. Breuer B, Wallenstein S, Anderson R. The effect of tamoxifen on bone fracture in older nursing home residents. J Am Geriatr Soc 1998;40: 968-972.
35. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996;14:78-84.
36. Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 1994;86:1534-1539.
37. Grey AB, Stapleton JP, Evans MC, Reid JR. The effect of the antiestrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 1995;80:3191-3195.
38. Guetta V, Lush RM, Figg WD, Waclawiw MA, Cannon RO III. Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal women. Am J Cardiol 1995;76:1672-1673.
39. Chang J, Powles TJ, Ashley SE, Gregory RK, Tidy VA, Treleaven JG, et al. The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. Ann Oncol 1996;7:671-675.
40. Shewmon DA, Stock JL, Rosen CJ, Heiniluoma KM, Hogue MM, Morrison A, et al. Tamoxifen and estrogen lower circulating lipoprotein (a) concentrations in healthy postmenopausal women. Arterioscler Thromb 1994;14:1586.
41. Cattaneo M, Baglietto L, Zighetti ML, Bettega D, Robertson C, Costa A, et al. Tamoxifen reduces plasma homocysteine levels in healthy women. Br J Cancer 1998;77:2264-2266.
42. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial: The Scottish Cancer Trials Breast Group. BMJ 1995;311:977-980.
43. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among post-menopausal women with early stage breast cancer in a randomized trial of adjuvant tamoxifen: The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993;85:1398-1406.
44. Schagen SB, van Dam F, Muller MJ, Boogerd W, Lindeboom J, Bruning P. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999;85:640-650.
45. Cyr M, Landry M, Dipaolo T. Modulation by estrogen receptor directed drugs of 5-hydroxytryptamine-2A receptors in rat brain. Neuropsychopharmacology 2000;23:69-77.
46. Lahti E, Blanco G, Kauppila A, Apaja-Saikkinen M, Taskinen PJ, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993;81:660-664.
47. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, et al. Effects of tamoxifen on the uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994;343:1318-1321.
48. Barakat RR. Tamoxifen and the endometrium. Cancer Treat Res 1998; 94:195-207.
49. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-537.
50. Stearns V, Gelman EP. Does tamoxifen cause cancer in humans? J Clin Oncol 1998;16:779.
51. Robinson E, Kimmick GG, Muss HB. Tamoxifen in postmenopausal women: A safety perspective. Drugs Aging 1996;8:329-337.
52. Hayes DF, Van Zyl JA, Hacking A, Goedhals L, Bezwoda WR, Mailliard JA, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 1995;13:2556.
53. Gershanovich M, Hayes DJ, Ellman J, Vuorinen J. High-dose toremifene versus tamoxifen in postmenopausal advanced breast cancer. Oncology (Huntingt) 1997;11(5 Suppl):29-36.
54. Marttunen MB, Hietanen P, Tiitinen A, Ylikorkala O. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab 1998;83:1158-1162.
55. Saarto T, Bomqvist C Ehnholm C, Taskinen MR, Elomma I. Antiatherogenic effects of adjuvant antiestrogens: A randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol 1996; 14:429-433.
56. Tomas E, Kauppila A, Blanco G, Apaja-Sarkkinen M, Laatikainen T. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol 1995; 59:261-266.
57. Davies GC, Huster WJ, Plouffe L, Lakshmanan M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999;93:558-565.
58. Jordan VC, Glusman JE, Eckert S, et al. Raloxifene reduces incident primary breast cancer; integrated data from multicenter, double-blind, randomized trials in postmenopausal women. Presented at the 21st Annual San Antonio Breast Cancer Symposium, December 12-15, 1998, San Antonio, TX.
59. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 1999;281:2189-2197.
60. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-1647.
61. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA 1999;282:637-645.
62. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445-1451.
63. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnand C. A controlled trial of raloxifene HCL: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996; 11:835-862.
64. Shughrue PJ, Lane MV, Merchenthaler I. Regulation of progesterone receptor messenger ribonucleic acid in the rat medial preoptic nucleus by estrogenic and antiestrogenic compounds: An in situ hybridization study. Endocrinology 1997;138:5476-5484.
65. Bryant HU, Bales KR, Paul SM, Yang H, Cole HW, Walker-Daniels J, et al. Estrogen agonist effects of selective estrogen receptor modulators in ovariectomized rat brain. Abstr Soc Neurosci 1997;23:2377 (abstract).
66. Cyr M, Landry M, DiPaolo T. Modulation by estrogen receptor directed drugs of 5-hydroxytryptamine-2A receptors in rat brain. Neuropsychopharmacology 2000;23:69-72.
67. Wu X, Glinn MA, Ostrowski NL, Su Y, Ni B, Cole HW, et al. Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomized rats. Brain Res 1999;847: 98-104.
68. Nickelsen T, Lufkin EG, Riggs BL, Cox DA, Crook TH. Raloxifene hydrochloride, a selective estrogen receptor modulator: Safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuroendocrinology 1999;24:115-128.
69. Yaffe K, Krueger K, Sarkar S, Grady D, Barrett-Connor E, Cox DA, et al. Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 2001;344:1207-1213.
70. Boss SM, Huster WJ, Neild JA, Glant MD, Eisenhut CC, Draper MW. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 1997;177:1458.
71. Cummings SR, Norton I, Eckert S, et al. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women: Two year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE Trial). Proc Am Soc Clin Oncol 1998; 17:2 (abstract).
72. Goldstein SR, Scheele WH, Rajagopalan SK, Wilkie JL, Walsh BW, Parsons AK. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol 2000;95: 95-103.
73. Ashby J, Odum J, Foster JR. Activity of raloxifene in immature and ovariectomized rat uterotrophic assays. Regul Toxicol Pharmacol 1997; 25:226-231.
74. Rauschning W, Pritchard KI. Droloxifene a new antiestrogen: Its role in metastatic breast cancer. Breast Cancer Res Treat 1994;31:83-94.
75. Eppenberger U, Wosikowski K, Kung W. Pharmacologic and biologic properties of droloxifene, a new antiestrogen. Am J Clin Oncol 1991; 14(Suppl 2):S5-S14.
76. Ke HZ, Chen HR, Simmons HA, Qi H, Crawford DT, Pirie CM, et al. Comparative effects of droloxifene, tamoxifene and estrogen on bone, serum cholesterol and uterine histology in the ovariectomized rat model. Bone 1997;20:31-39.
77. Herrington DM, Pusser BE, Riley WA, Thuren TY, Brosnihan KB, Brinton EA, et al. Cardiovascular effects of droloxifene. A new selective estrogen receptor modulator in healthy postmenopausal women. Arterioscler Thromb Vasc Biol 2000;20:1606-1612.
78. Weiss S, Mulder H, Chestnut C, et al. Idoxifene reduces bone turnover in osteopenic postmenopausal women. Presented at the 80th annual meeting of the Endocrine Society, June 24-27, 1998, New Orleans, LA (abstract).
79. Bolognese M, Moffett A, Jensen C, et al. Idoxifene is well tolerated in osteopenic postmenopausal women. Presented at the ninth annual meeting of the North American Menopause Society, September 16-19, 1998, Toronto (abstract 98).
80. Toko T, Sugimoto Y, Matsuo K, Yamasaki R, Takeda S, Wierzba K, et al. TAT 59: A new triphenylethylene derivative with antitumor activity against hormone-dependent tumors. Eur J Cancer 1990;26:397-404.
81. Shibata J, Toko T, Saito H, Lykkesfeldt AE, Fujioka A, Sako K, et al. Estrogen agonistic/antagonistic effects of miproxifene phosphate (TAT 59). Cancer Chemother Pharmacol 2000;45:133-141.
82. Qu Q, Zheng H, Dahllund J, Laine A, Cockcroft N, Peng Z, et al. Selective estrogenic effects of a novel triphenylethylene compound FC1211a on bone, cholesterol levels, and reproductive tissues in intact and ovariectomized rats. Endocrinology 2000;141:809-820.
83. Sato M, Turner CH, Wang T, Adrian MD, Rowley E, Bryant HU. LY353381.HCl: A novel raloxifene analogue with improved SERM potency and efficacy in vivo. J Pharmacol Exp Ther 1998;287:1-7.
84. Munster PN, Buzdar A, Dhingra K, Enas N, Ni L, Major M, et al. Phase I study of a third generation selective estrogen receptor modulator Ly353381.HCL in metastatic breast cancer. J Clin Oncol 2001;19:2002-2004.